PT  - JOURNAL ARTICLE
AU  - Dominick E. Shaw
AU  - Ana R. Sousa
AU  - Stephen J. Fowler
AU  - Louise J. Fleming
AU  - Graham Roberts
AU  - Julie Corfield
AU  - Ioannis Pandis
AU  - Aruna T. Bansal
AU  - Elisabeth H. Bel
AU  - Charles Auffray
AU  - Chris H. Compton
AU  - Hans Bisgaard
AU  - Enrica Bucchioni
AU  - Massimo Caruso
AU  - Pascal Chanez
AU  - Barbro Dahlén
AU  - Sven-Erik Dahlen
AU  - Kerry Dyson
AU  - Urs Frey
AU  - Thomas Geiser
AU  - Maria Gerhardsson de Verdier
AU  - David Gibeon
AU  - Yi-ke Guo
AU  - Simone Hashimoto
AU  - Gunilla Hedlin
AU  - Elizabeth Jeyasingham
AU  - Pieter-Paul W. Hekking
AU  - Tim Higenbottam
AU  - Ildikó Horváth
AU  - Alan J. Knox
AU  - Norbert Krug
AU  - Veit J. Erpenbeck
AU  - Lars X. Larsson
AU  - Nikos Lazarinis
AU  - John G. Matthews
AU  - Roelinde Middelveld
AU  - Paolo Montuschi
AU  - Jacek Musial
AU  - David Myles
AU  - Laurie Pahus
AU  - Thomas Sandström
AU  - Wolfgang Seibold
AU  - Florian Singer
AU  - Karin Strandberg
AU  - Jorgen Vestbo
AU  - Nadja Vissing
AU  - Christophe von Garnier
AU  - Ian M. Adcock
AU  - Scott Wagers
AU  - Anthony Rowe
AU  - Peter Howarth
AU  - Ariane H. Wagener
AU  - Ratko Djukanovic
AU  - Peter J. Sterk
AU  - Kian Fan Chung
TI  - Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
AID  - 10.1183/13993003.00779-2015
DP  - 2015 Nov 01
TA  - European Respiratory Journal
PG  - 1308--1321
VI  - 46
IP  - 5
4099  - http://erj.ersjournals.com/content/46/5/1308.short
4100  - http://erj.ersjournals.com/content/46/5/1308.full
SO  - Eur Respir J2015 Nov 01; 46
AB  - U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.Severe asthma results in more airway inflammation, worse symptoms and lower lung function, despite increased therapy http://ow.ly/QznR3